



Commercial/Healthcare Exchange PA Criteria Effective: May 12, 2022

Prior Authorization: Vonjo

Products Affected: Vonjo (pacritinib) oral capsules

Medication Description: Vonjo, an inhibitor of Janus Associated Kinase (*JAK*) 2 and FMS-like tyrosine kinase (*FLT3*), is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×10^9 /L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Covered Uses: Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×10^9 /L.

Exclusion Criteria:

1. Contraindicated in patients concomitantly using strong CYP3A4 inhibitors or inducers
2. Concurrent use with other kinase inhibitors (Prior to initiation must taper or discontinue)

Required Medical Information:

1. Diagnosis

Prescriber Restriction: Prescribed by, or in consultation with, a hematologist or oncologist.

Age Restriction: 18 years of age or older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. **Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF.**
Approve for 1 year if the patient meets ALL of the following criteria:
 - A. Patient has intermediate risk or high-risk disease; **AND**
 - B. Patient has a platelet count of less than 50×10^9 /L (< 50,000/mcL)

Renewal Criteria

- A. Member has responded positively to the treatment as determined by the prescribing physician; **AND**
- B. Member has not experienced unacceptable toxicity from the drug.

May 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



References:

1. Vonjo® capsules [prescribing information]. Seattle, WA: CTI BioPharma; February 2022.
2. The NCCN Myeloproliferative Neoplasms Clinical Practice Guidelines in Oncology (version 1.2022 – February 28, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on April 20, 2022

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	5/12/2022

